-
1.发明授权USE OF A FATTY ACID COMPOSITION COMPRISING AT LEAST ONE OF EPA AND DHA OR ANY COMBINATIONS THEREOF 有权使用一种脂肪酸组合物至少含有具有EPA和DHA或它们的任意组合
公开(公告)号：EP1699449B1
公开(公告)日：2014-01-22
申请号：EP04806374.7
申请日：2004-12-17
发明人： BRYHN, Morten , KOPECKY, Jan
IPC分类号： A61K31/202 , A61K31/557 , A23L1/307 , A61P3/04
CPC分类号： A23L1/3008 , A23L33/12 , A23L33/30 , A23V2002/00 , A61K31/202 , A61K31/232 , A61K31/557 , A61K45/06 , A61K2300/00 , A23V2200/332 , A23V2250/187 , A23V2250/1868
-
2.发明公开ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). 审中-公开α-取代的ω-3脂质它们活化剂或调节剂的过氧化物酶体受体（PPAR）PRICE
公开(公告)号：EP2094640A1
公开(公告)日：2009-09-02
申请号：EP07825558.5
申请日：2007-11-01
IPC分类号： C07C69/587 , A61K31/202 , A61K31/232 , A61P1/16 , A61P29/00 , A61P3/04 , A61P3/10 , C07C229/30 , C07C323/54 , C07C57/13 , C07C69/602 , C07C69/732 , C07C69/734 , C11C3/00 , A61K49/00
CPC分类号： C07C323/54 , A23D9/00 , A61K49/0004 , C07C57/03 , C07C57/12 , C07C69/587 , C07C211/20 , C07C229/30 , C07F9/091 , C07F9/106 , C07H15/04
摘要： Omega-3 lipid compounds of the general formula (I): wherein R1 and R2 are the same or different and may be selected from a group of substitu- ents consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an al- kynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, a car- boxy group, an alkylsulfmyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; - X represents a carboxylic acid or a derivative thereof, a carboxylate, a carboxylic anhydride or a carboxamide; and - Y is a C16 to C22 alkene with two or more double bonds, having E and/or Z configuration, are disclosed. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments in particular for the treatment of cardiovascular and metabolic diseases.
-
3.发明公开FATTY ACID ANALOGUES, I.E. DHA DERIVATIVES FOR USES AS A MEDICAMENT 审中-公开脂肪酸ANALOG，D. H. DHA衍生物用作药物
公开(公告)号：EP1888728A1
公开(公告)日：2008-02-20
申请号：EP06755858.5
申请日：2006-05-04
IPC分类号： C11C3/00 , A61K31/202 , A61K31/232 , A61P3/04 , A61P3/10 , A61P9/10 , C07C57/03 , C07C69/587
CPC分类号： C07C57/03 , C07C69/587 , C07C69/618 , C07C69/65 , C07C69/732 , C07C69/734 , C07C229/30 , C07C233/09 , C07C235/28 , C07C237/16 , C07C317/44 , C07C323/54 , C07D209/48 , C07D263/22 , C07D263/24 , C11C3/00
摘要： A compound of formula (I), wherein one of R1 and R2 is a methyl group and the other of R1 and R2 is a hydrogen atom; wherein X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, for use as a medicament, is disclosed. A pharmaceutical composition and a fatty acid composition comprising a compound of formula (I) is also disclosed. The use of a compound of formula (I) for the manufacture of a medicament, in particular for the treatment of diabetes type 2, is also disclosed.
-
公开(公告)号：EP1888727B1
公开(公告)日：2015-04-15
申请号：EP06744648.4
申请日：2006-05-04
IPC分类号： C11C3/00 , A61K31/202 , A61K31/232 , A61K31/421 , A61P3/04 , A61P3/10 , A61P9/10 , C07C57/03 , C07C69/587 , C07D263/24
CPC分类号： C07C57/03 , C07C69/587 , C07C69/618 , C07C69/65 , C07C69/732 , C07C69/734 , C07C229/30 , C07C233/09 , C07C235/28 , C07C237/16 , C07C317/44 , C07C323/54 , C07D209/48 , C07D263/22 , C07D263/24 , C11C3/00
-
公开(公告)号：EP1888727A1
公开(公告)日：2008-02-20
申请号：EP06744648.4
申请日：2006-05-04
IPC分类号： C11C3/00 , A61K31/202 , A61K31/232 , A61K31/421 , A61P3/04 , A61P3/10 , A61P9/10 , C07C57/03 , C07C69/587 , C07D263/24
CPC分类号： C07C57/03 , C07C69/587 , C07C69/618 , C07C69/65 , C07C69/732 , C07C69/734 , C07C229/30 , C07C233/09 , C07C235/28 , C07C237/16 , C07C317/44 , C07C323/54 , C07D209/48 , C07D263/22 , C07D263/24 , C11C3/00
摘要： Compounds of formula (I); wherein - R1 and R2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfmyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and - X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19- docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
